This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Merke, D. P. Search for Related Content PubMed PubMed Citation Articles by Merke, D. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 17ALPHA-HYDROXYPROGESTERONE FLUDROCORTISONE Related Collections Adrenal and Hypertension Pediatric Endocrinology

Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency

National Institutes of Health Clinical Center and Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1932

Address all correspondence and requests for reprints to: Deborah P. Merke, M.D., M.S., National Institutes of Health Clinical Center, Building 10-CRC, Room 1-2740, Bethesda, Maryland 20892-1932. E-mail: dmerke{at}mail.nih.gov.

Congenital adrenal hyperplasia (CAH) describes a group of autosomal recessive disorders where there is impairment of cortisol biosynthesis. CAH due to 21-hydroxylase deficiency accounts for 95% of cases and shows a wide range of clinical severity. Treatment of the classic or severe form of CAH is targeted at replacing cortisol and aldosterone and effectively controlling excess androgen symptoms by using the lowest possible glucocorticoid dose. Treatment of the mild or nonclassic form is targeted at controlling excess androgen symptoms and may or may not involve glucocorticoid therapy. Hydrocortisone is the treatment of choice for children, but there is no consensus on how patients should be treated as adults. Current glucocorticoid therapy is suboptimal because it is often difficult to reduce excess androgen without giving excess glucocorticoid, and patients may experience hypercortisolism, androgen excess, or a combination of these states. Treatment of CAH, especially in the adult patient, remains controversial given the lack of prospective randomized controlled trials comparing treatment regimens. Nevertheless, patients benefit from careful individualized therapy with avoidance of Cushingoid side effects and optimization of reproductive, sexual, and bone health.